Key points are not available for this paper at this time.
You have accessJournal of UrologyKidney Cancer: Epidemiology 9,365 patients had primary renal tumors (arising in the kidney or renal pelvis), and 8,090 patients had primary ureteral tumors. We retrospectively analyzed trends in overall survival and 30- and 90-day mortality. RESULTS: In the 9,365 patients with primary renal or renal pelvis tumors, 68.3% had cT1 disease and 31.7% had cT2-4 disease. Additionally, 4,332 (46.3%) underwent LND with 4.6% having pN+ disease. LND was associated with lower overall mortality when compared with no LND (36.6% versus 43.4%, p<0.001). In the 8,090 patients with primary ureteral tumors, 71% had cT1 disease and 29% had cT2-4 disease. Furthermore, 3,866 (47.8%) underwent LND and 3.2% had pN+ disease. Similarly, LND was associated with lower overall mortality when compared with no LND (37.2% versus 49.7%, p<0.001). However, LND was not associated with mortality within 30- or 90-days in either group. CONCLUSIONS: LND in the setting of radical nephroureterectomy or ureterectomy is underutilized, with less than half of patients with primary renal or primary ureteral tumors receiving LND from 2006-2016. Our analysis demonstrates a potential survival benefit associated with LND for patients with UTUC. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e850 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Abigail L. Kohut-Jackson More articles by this author Krithika Kumanan More articles by this author Zachary Hamilton More articles by this author Expand All Advertisement PDF downloadLoading ...
Kohut-Jackson et al. (Mon,) studied this question.